1st Quarter - Report

BROWN RUDNICK LLP for APOTEX CORPORATION

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 1315 & H.R. 3777 - The Drug Price Competition Act of 2009; H.R. 3962 - Affordable Healthcare for American Act; H.R. 3590 - Patient Protection and Affordability Act; H.R. 1706 Protecting Consumer Access to Generic Drugs Act; S. 369 - Preserve Access to Affordable Generics Act

Foreign entity interest: Apotex Holdings Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen Stabenow(05-07)
HENRY W MENN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1315 (111th), H.R. 1706 (111th), H.R. 3777 (111th), H.R. 3962 (111th), S. 369 (111th), H.R. 3590 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.